Cardioprotective action of alpha-blocking agents, phentolamine and bunazosin, on hypoxic and reoxygenated myocardium.
The present study was undertaken to determine whether alpha-blocking agents, phentolamine and bunazosin, may exert a cardioprotective effect on hypoxic and subsequently reoxygenated hearts. For this purpose, rabbit hearts were perfused for 20 min under hypoxic conditions, followed by a 45 min-reoxygenation. Agents were administered between the 8th and 20th min of hypoxic perfusion. Hypoxic perfusion for 8 min resulted in a decline of cardiac contractile force and myocardial high-energy phosphates and a loss of adenine nucleotide metabolites from the heart, whereas a rise in resting tension was not observed. Neither increase in perfusion pressure, release of creatine kinase from hearts nor increase in tissue calcium was observed. At 20 min-hypoxia, significant changes in resting tension and perfusion pressure of the heart and release of creatine kinase from the heart were observed. Cardiac contractile force after 45 min of reoxygenation was less than 10% of the initial value. Treatment with 83 microM phentolamine or 46 microM of bunazosin resulted in a significant suppression of hypoxia-induced increase in tissue calcium, release of creatine kinase and adenine nucleotide metabolites and rise in perfusion pressure and resting tension. Treatment with either phentolamine or bunazosin resulted in appreciable recovery of cardiac contractile force. Reoxygenation-induced release of creatine kinase was also suppressed significantly. Two possible mechanisms for the protective effect of this treatment are considered; 1) preservation of ATP metabolites which may be utilized as substrates for a salvage synthesis of ATP during reoxygenation and 2) prevention of a nonselective transmembrane flux of cellular constituents due to changes in cell membrane permeability.
D000255:Adenosine Triphosphate / Q000378:metabolism; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D004734:Energy Metabolism / Q000187:drug effects; D006321:Heart / Q000187:drug effects*; D000860:Hypoxia / Q000378:metabolism*; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism; D010100:Oxygen; D010646:Phentolamine / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D011817:Rabbits
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D000255:Adenosine Triphosphate; C018176:bunazosin; D010100:Oxygen; D010646:Phentolamine